BAY80-6946 |
BAY 80-6946 |
COPANLISIB |
BAY-80-6946 |
chembl:CHEMBL3218576 |
chemidplus:1032568-63-0 |
pubchem.compound:24989044 |
drugbank:12483 |
Notes | pan-PI3K inhibitor |
Drug Class | Kinase Inhibitors |
Pharmaceutical Developer | Bayer |
Source Reported Drug Name(s) | BAY80-6946 |
Drug Class | PI3K Inhibitor |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
Drug Categories | antineoplastic agents |
Drug Categories | antineoplastic and immunomodulating agents |
Drug Categories | bcrp/abcg2 substrates |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 substrates |
Drug Categories | cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 cyp3a5 substrates |
Drug Categories | cytochrome p-450 cyp3a7 substrates |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | heterocyclic compounds, fused-ring |
Drug Categories | kinase inhibitor |
Drug Categories | mate 2 inhibitors |
Drug Categories | mate inhibitors |
Drug Categories | p-glycoprotein substrates |
Drug Categories | p-glycoprotein substrates with narrow therapeutic index |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | PI3-kinase class I inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction? | False |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Direct Interaction? | False |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
n/a |
Indication/Tumor Type | endometrial carcinoma |
Response Type | sensitive |
Approval Status | Phase I |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
66563707 | PubChem Drug ID |
Drug Class | PI3K Inhibitor |
Source Reported Drug Name(s) | BAY80-6946 |
Pharmaceutical Developer | Bayer |
COPANLISIB | DrugBank Drug Name |
1032568-63-0 | CAS Number |
Aliqopa | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
Drug Class | Kinase Inhibitors |
Notes | pan-PI3K inhibitor |
COPANLISIB | GuideToPharmacology Ligand Name |